Spondyloarthritis & psoriatic arthritis
Impact of treatments on fatigue in axial spondyloarthritis: a systematic review and meta-analysis
Authors' conclusion
This review shows a beneficial effect of DMARD and non-pharmacological treatment on fatigue in axSpA in short and medium terms with a greater effect when combining them.
Study context
- Population
- Patients with axial SpA (axSpA) meeting the ASAS 2009 criteria, fatigue measured between 12 and 156 weeks of treatment34 studies
- Comparison
- axSpA treatments and their effect on fatigue
- Outcome
- Fatigue
- Follow-up
- 12 to 156 weeks of treatment
Methodological detailsPRISMA, meta-analysis of TNFi/anti-IL-17/JAKi RCTs at week 12-16
- PRISMA
- Meta-analysis of TNFi/anti-IL-17/JAKi RCTs at week 12-16
Pooled result
As reported in the abstract
Anti-IL-17: reduction in fatigue in three of four studies, with a dose effect for secukinumab
3
JAKi: reduction in fatigue in two studies
2
Further pooled results
Physical activity added to anti-TNF
- Greater fatigue reduction in two studies
- 2
Efficacy by sex and by form
- Greater efficacy in men (one study)
- 1
- Greater efficacy suggested in non-radiographic form (two studies)
- 2
Original publication
Impact of treatments on fatigue in axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford). Published 10 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →